IBD candidate genes and intestinal barrier regulation

Inflammatory Bowel Diseases

Volumn 20, Issue 10, 2014, Pages 1829-1849

  McCole, Declan F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epithelial; Inflammation; Permeability; Tight junctions

Indexed keywords

GLYCOPROTEIN; IMMUNOGLOBULIN A; PROTEIN TYROSINE PHOSPHATASE; UVOMORULIN; BIOLOGICAL MARKER;

CELL ADHESION; CELL POLARITY; CROHN DISEASE; ELECTROLYTE TRANSPORT; FLUID TRANSPORT; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE EPITHELIUM; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; MEMBRANE TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; REVIEW; TIGHT JUNCTION; ULCERATIVE COLITIS; GENE EXPRESSION REGULATION; GENE LOCUS; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; INTESTINE MUCOSA; METABOLISM; PATHOLOGY;

BIOMARKERS; GENE EXPRESSION REGULATION; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA;

EID: 84925504604     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000090     Document Type: Review

References (299)

1. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
2. Jager S, Stange EF, Wehkamp J. Inflammatory bowel disease: an impaired barrier disease. Langenbecks Arch Surg. 2013;398:1-12.
3. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307-317.
4. McGuckin MA, Eri R, Simms LA, et al. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis. 2009;15:100-113.
5. Thompson AI, Lees CW. Genetics of ulcerative colitis. Inflamm Bowel Dis. 2011;17:831-848.
6. Odenwald MA, Turner JR. Intestinal permeability defects: is it time to treat? Clinical gastroenterology and hepatology. Clin Gastroenterol Hepatol. 2013;11:1075-1083.
7. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573-621.
8. McCole DF, Barrett KE. Varied role of the gut epithelium in mucosal homeostasis. Curr Opin Gastroenterol. 2007;23:647-654.
9. Goto Y, Kiyono H. Epithelial barrier: an interface for the crosscommunication between gut flora and immune system. Immunol Rev. 2012;245:147-163.
10. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis. 2010;16:1583-1597.
11. Dahan S, Roth-Walter F, Arnaboldi P, et al. Epithelia: lymphocyte interactions in the gut. Immunol Rev. 2007;215:243-253.
12. McDole JR, Wheeler LW, McDonald KG, et al. Goblet cells deliver luminal antigen to CD103+ dendritic cells in the small intestine. Nature. 2012;483:345-349.
13. McCole DF, Barrett KE. Epithelial transport and gut barrier function in colitis. Curr Opin Gastroenterol. 2003;19:578-582.
14. Montrose MH, Keely SJ, Barrett KE. Electrolyte secretion and absorption: small intestine and colon. In: Yamada T, ed. Textbook of Gastroenterology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003:308-339.
15. Garcia MA, Yang N, Quinton PM. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest. 2009;119:2613-2622.
16. Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet. 2008;372:415-417.
17. Hansson GC. Role of mucus layers in gut infection and inflammation. Curr Opin Microbiol. 2012;15:57-62.
18. Johansson ME, Phillipson M, Petersson J, et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A. 2008;105:15064-15069.
19. Kawashima H. Roles of the gel-forming MUC2 mucin and its O-glycosylation in the protection against colitis and colorectal cancer. Biol Pharm Bull. 2012;35:1637-1641.
20. Canny G, Levy O, Furuta GT, et al. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A. 2002;99:3902-3907.
21. Cash HL, Whitham CV, Behrendt CL, et al. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science. 2006;313:1126-1130.
22. Schauber J, Rieger D, Weiler F, et al. Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2006;18:615-621.
23. Marquez A, Varade J, Robledo G, et al. Specific association of a CLEC16A/KIAA0350 polymorphism with NOD2/CARD15 (-) Crohn's disease patients. Eur J Hum Genet. 2009;17:1304-1308.
24. Van Dussen KL, Liu TC, Li D, et al. Genetic variants synthesize to produce paneth cell phenotypes that define subtypes of Crohn's disease. Gastroenterology. 2014;146:200-209.
25. Kaetzel CS. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol Rev. 2005;206:83-99.
26. Cerutti A, Rescigno M. The biology of intestinal immunoglobulin A responses. Immunity. 2008;28:740-750.
27. Apter FM, Lencer WI, Finkelstein RA, et al. Monoclonal immunoglobulin A antibodies directed against cholera toxin prevent the toxininduced chloride secretory response and block toxin binding to intestinal epithelial cells in vitro. Infect Immunity. 1993;61:5271-5278.
28. Mantis NJ, Rol N, Corthesy B. Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol. 2011;4:603-611.
29. Sekirov I, Russell SL, Antunes LC, et al. Gut microbiota in health and disease. Physiol Rev. 2010;90:859-904.
30. Stokes CR, Soothill JF, Turner MW. Immune exclusion is a function of IgA. Nature. 1975;255:745-746.
31. Talbot C, Lytle C. Segregation of Na/H exchanger-3 and Cl/HCO3 exchanger SLC26A3 (DRA) in rodent cecum and colon. Am J Physiol Gastrointest Liver Physiol. 2010;299:G358-G367.
32. Kiela PR, Laubitz D, Larmonier CB, et al. Changes in mucosal homeostasis predispose NHE3 knockout mice to increased susceptibility to DSS-induced epithelial injury. Gastroenterology. 2009;137:965-975. e961-e910.
33. Larmonier CB, Laubitz D, Thurston RD, et al. NHE3 modulates the severity of colitis in IL-10-deficient mice. Am J Physiol Gastrointest Liver Physiol. 2011;300:G998-G1009.
34. Walker NM, Simpson JE, Brazill JM, et al. Role of down-regulated in adenoma anion exchanger in HCO3-secretion across murine duodenum. Gastroenterology. 2009;136:893-901.
35. Walker NM, Simpson JE, Yen PF, et al. Down-regulated in adenoma Cl/HCO3 exchanger couples with Na/H exchanger 3 for NaCl absorption in murine small intestine. Gastroenterology. 2008;135:1645-1653. e1643.
36. Xiao F, Juric M, Li J, et al. Loss of downregulated in adenoma (DRA) impairs mucosal HCO3 (-) secretion in murine ileocolonic inflammation. Inflamm Bowel Dis. 2012;18:101-111.
37. Simms LA, Doecke JD, Roberts RL, et al. KCNN4 gene variant is associated with ileal Crohn's Disease in the Australian and New Zealand population. Am J Gastroenterol. 2010;105:2209-2217.
38. Flores CA, Melvin JE, Figueroa CD, et al. Abolition of Ca2+-mediated intestinal anion secretion and increased stool dehydration in mice lacking the intermediate conductance Ca2+-dependent K+ channel Kcnn4. J Physiol. 2007;583:705-717.
39. Di L, Srivastava S, Zhdanova O, et al. Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis. Proc Natl Acad Sci U S A. 2010;107:1541-1546.
40. Powell DW. Barrier function of epithelia. Am J Physiol. 1981;241:G275-G288.
41. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9:799-809.
42. Ivanov AI, Parkos CA, Nusrat A. Cytoskeletal regulation of epithelial barrier function during inflammation. Am J Pathol. 2010;177:512-524.
43. Koch S, Nusrat A. Dynamic regulation of epithelial cell fate and barrier function by intercellular junctions. Ann N Y Acad Sci. 2009;1165:220-227.
44. Anderson JM, Van Itallie CM. Physiology and function of the tight junction. Cold Spring Harb Perspect Biol. 2009;1:a002584.
45. Angelow S, Ahlstrom R, Yu AS. Biology of claudins. Am J Physiol Renal Physiol. 2008;295:F867-F876.
46. Gonzalez-Mariscal L, Tapia R, Chamorro D. Crosstalk of tight junction components with signaling pathways. Biochim Biophys Acta. 2008;1778:729-756.
47. Gunzel D, Fromm M. Claudins and other tight junction proteins. Compr Physiol. 2012;2:1819-1852.
48. Nusrat A, Turner JR, Madara JL. Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am J Physiol Gastrointest Liver Physiol. 2000;279:G851-G857.
49. Shen L, Weber CR, Raleigh DR, et al. Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol. 2011;73:283-309.
50. Hartsock A, Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta. 2008;1778:660-669.
51. Claude P. Morphological factors influencing transepithelial permeability: a model for the resistance of the zonula occludens. J Membr Biol. 1978;39:219-232.
52. Matter K, Balda MS. Signalling to and from tight junctions. Nat Rev Mol Cell Biol. 2003;4:225-236.
53. Steed E, Balda MS, Matter K. Dynamics and functions of tight junctions. Trends Cell Biol. 2010;20:142-149.
54. Wada M, Tamura A, Takahashi N, et al. Loss of claudins 2 and 15 from mice causes defects in paracellular Na+ flow and nutrient transport in gut and leads to death from malnutrition. Gastroenterology. 2013;144:369-380.
55. Saitou M, Furuse M, Sasaki H, et al. Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol Biol Cell. 2000;11:4131-4142.
56. Al-Sadi R, Boivin M, Ma T. Mechanism of cytokine modulation of epithelial tight junction barrier. Front Biosci (Landmark Ed). 2009;14:2765-2778.
57. Marchiando AM, Shen L, Graham WV, et al. Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo. J Cell Biol. 2010;189:111-126.
58. Van Itallie CM, Fanning AS, Holmes J, et al. Occludin is required for cytokine-induced regulation of tight junction barriers. J Cell Sci. 2010;123:2844-2852.
59. Yu AS, McCarthy KM, Francis SA, et al. Knockdown of occludin expression leads to diverse phenotypic alterations in epithelial cells. Am J Physiol Cell Physiol. 2005;288:C1231-C1241.
60. Furuse M, Itoh M, Hirase T, et al. Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. J Cell Biol. 1994;127:1617-1626.
61. Nusrat A, Chen JA, Foley CS, et al. The coiled-coil domain of occludin can act to organize structural and functional elements of the epithelial tight junction. J Biol Chem. 2000;275:29816-29822.
62. Van Itallie CM, Anderson JM. Occludin confers adhesiveness when expressed in fibroblasts. J Cell Sci. 1997;110:1113-1121.
63. Meddings J. The significance of the gut barrier in disease. Gut. 2008;57:438-440.
64. Meddings J. What role does intestinal permeability have in IBD pathogenesis? Inflamm Bowel Dis. 2008;14(suppl 2):S138-S139.
65. Teshima CW, Dieleman LA, Meddings JB. Abnormal intestinal permeability in Crohn's disease pathogenesis. Ann N Y Acad Sci. 2012;1258:159-165.
66. Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol. 2000;35:1163-1169.
67. Wyatt J, Vogelsang H, Hubl W, et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet. 1993;341:1437-1439.
68. Hollander D, Vadheim CM, Brettholz E, et al. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med. 1986;105:883-885.
69. Irvine EJ, Marshall JK. Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology. 2000;119:1740-1744.
70. May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn's disease? Gastroenterology. 1993;104:1627-1632.
71. Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut. 2006;55:1512-1520.
72. Menzies IS, Laker MF, Pounder R, et al. Abnormal intestinal permeability to sugars in villous atrophy. Lancet. 1979;2:1107-1109.
73. Marin ML, Greenstein AJ, Geller SA, et al. A freeze fracture study of Crohn's disease of the terminal ileum: changes in epithelial tight junction organization. Am J Gastroenterol. 1983;78:537-547.
74. Weber CR, Raleigh DR, Su L, et al. Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J Biol Chem. 2010;285:12037-12046.
75. Zeissig S, Burgel N, Gunzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut. 2007;56:61-72.
76. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121:580-591.
77. Olson TS, Reuter BK, Scott KG, et al. The primary defect in experimental ileitis originates from a nonhematopoietic source. J Exp Med. 2006;203:541-552.
78. Resta-Lenert S, Smitham J, Barrett KE. Epithelial dysfunction associated with the development of colitis in conventionally housed mdr1a-/-mice. Am J Physiol Gastrointest Liver Physiol. 2005;289:G153-G162.
79. Clayburgh DR, Barrett TA, Tang Y, et al. Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. The J Clinical Investigation. 2005;115:2702-2715.
80. Shen L, Black ED, Witkowski ED, et al. Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure. J Cell Sci. 2006;119:2095-2106.
81. Su L, Shen L, Clayburgh DR, et al. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology. 2009;136:551-563.
82. Arrieta MC, Madsen K, Doyle J, et al. Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse. Gut. 2009;58:41-48.
83. Salim SY, Soderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:362-381.
84. Schurmann G, Bruwer M, Klotz A, et al. Transepithelial transport processes at the intestinal mucosa in inflammatory bowel disease. Int J Colorectal Dis. 1999;14:41-46.
85. Soderholm JD, Streutker C, Yang PC, et al. Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor alpha. Gut. 2004;53:1817-1824.
86. Camilleri M, Madsen K, Spiller R, et al. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterology and motility. Neurogastroenterol Motil. 2012;24:503-512.
87. Van Sommeren S, Visschedijk MC, Festen EA, et al. HNF4alpha and CDH1 are associated with ulcerative colitis in a Dutch cohort. Inflamm Bowel Dis. 2011;17:1714-1718.
88. Consortium UIG, Barrett JC, Lee JC, et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet. 2009;41:1330-1334.
89. McGovern DP, Gardet A, Torkvist L, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet. 2010;42:332-337.
90. Muise AM, Walters TD, Glowacka WK, et al. Polymorphisms in E-cadherin (CDH1) result in a mis-localised cytoplasmic protein that is associated with Crohn's disease. Gut. 2009;58:1121-1127.
91. Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science. 1995;270:1203-1207.
92. Bonazzi M, Cossart P. Impenetrable barriers or entry portals? the role of cell-cell adhesion during infection. J Cell Biol. 2011;195:349-358.
93. Demetter P, De Vos M, Van Damme N, et al. Focal up-regulation of E-cadherin-catenin complex in inflamed bowel mucosa but reduced expression in ulcer-associated cell lineage. Am J Clin Pathol. 2000;114:364-370.
94. Karayiannakis AJ, Syrigos KN, Efstathiou J, et al. Expression of catenins and E-cadherin during epithelial restitution in inflammatory bowel disease. J Pathol. 1998;185:413-418.
95. Hazan RB, Qiao R, Keren R, et al. Cadherin switch in tumor progression. Ann N Y Acad Sci. 2004;1014:155-163.
96. Houlston RS, Webb E, Broderick P, et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet. 2008;40:1426-1435.
97. Klucky B, Mueller R, Vogt I, et al. Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion. Cancer Res. 2007;67:8198-8206.
98. Machado JC, Oliveira C, Carvalho R, et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene. 2001;20:1525-1528.
99. Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013;145:166-175. e168.
100. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.
101. Azarschab P, Porschen R, Gregor M, et al. Epigenetic control of the E-cadherin gene (CDH1) by CpG methylation in colectomy samples of patients with ulcerative colitis. Genes Chromosomes Cancer. 2002;35:121-126.
102. Silverberg MS, Cho JH, Rioux JD, et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet. 2009;41:216-220.
103. Teller IC, Beaulieu JF. Interactions between laminin and epithelial cells in intestinal health and disease. Expert Rev Mol Med. 2001;3:1-18.
104. Timpl R, Brown JC. Supramolecular assembly of basement membranes. BioEssays. 1996;18:123-132.
105. Miner JH, Yurchenco PD. Laminin functions in tissue morphogenesis. Annu Rev Cell Dev Biol. 2004;20:255-284.
106. Beaulieu JF, Vachon PH. Reciprocal expression of laminin A-chain isoforms along the crypt-villus axis in the human small intestine. Gastroenterology. 1994;106:829-839.
107. Simon-Assmann P, Duclos B, Orian-Rousseau V, et al. Differential expression of laminin isoforms and alpha 6-beta 4 integrin subunits in the developing human and mouse intestine. Dev Dyn. 1994;201:71-85.
108. Vachon PH, Beaulieu JF. Extracellular heterotrimeric laminin promotes differentiation in human enterocytes. Am J Physiol. 1995;268:G857-G867.
109. Koutroubakis IE, Petinaki E, Dimoulios P, et al. Serum laminin and collagen IV in inflammatory bowel disease. J Clin Pathol. 2003;56:817-820.
110. Schmehl K, Florian S, Jacobasch G, et al. Deficiency of epithelial basement membrane laminin in ulcerative colitis affected human colonic mucosa. Int J Colorectal Dis. 2000;15:39-48.
111. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008;40:955-962.
112. Bouatrouss Y, Herring-Gillam FE, Gosselin J, et al. Altered expression of laminins in Crohn's disease small intestinal mucosa. Am J Pathol. 2000;156:45-50.
113. Francoeur C, Escaffit F, Vachon PH, et al. Proinflammatory cytokines TNF-alpha and IFN-gamma alter laminin expression under an apoptosisindependent mechanism in human intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2004;287:G592-G598.
114. Saito E, Okamoto A, Saito M, et al. Genes associated with the genesis of leiomyoma of the uterus in a commonly deleted chromosomal region at 7q22. Oncol Rep. 2005;13:469-472.
115. Saito N, Kameoka S. Serum laminin is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis. 2005;20:238-244.
116. Wapenaar MC, Monsuur AJ, Van Bodegraven AA, et al. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis. Gut. 2008;57:463-467.
117. Wolters VM, Xu W, Zhao X, et al. Replication of genetic variation in the MYO9B gene in Crohn's disease. Hum Immunol. 2011;72:592-597.
118. Schumann M, Gunzel D, Buergel N, et al. Cell polarity-determining proteins Par-3 and PP-1 are involved in epithelial tight junction defects in coeliac disease. Gut. 2012;61:220-228.
119. Ebnet K, Suzuki A, Horikoshi Y, et al. The cell polarity protein ASIP/PAR-3 directly associates with junctional adhesion molecule (JAM). EMBO J. 2001;20:3738-3748.
120. Helfrich I, Schmitz A, Zigrino P, et al. Role of aPKC isoforms and their binding partners Par3 and Par6 in epidermal barrier formation. J Invest Dermatol. 2007;127:782-791.
121. Hurd TW, Fan S, Liu CJ, et al. Phosphorylation-dependent binding of 14-3-3 to the polarity protein Par3 regulates cell polarity in mammalian epithelia. Curr Biol. 2003;13:2082-2090.
122. Lemmers C, Michel D, Lane-Guermonprez L, et al. CRB3 binds directly to Par6 and regulates the morphogenesis of the tight junctions in mammalian epithelial cells. Molecular Biology of the Cell. 2004;15:1324-1333.
123. Shin K, Wang Q, Margolis B. PATJ regulates directional migration of mammalian epithelial cells. EMBO Reports. 2007;8:158-164.
124. Du D, Xu F, Yu L, et al. The tight junction protein, occludin, regulates the directional migration of epithelial cells. Developmental Cell. 2010;18:52-63.
125. Neer EJ. Heterotrimeric G proteins: organizers of transmembrane signals. Cell. 1995;80:249-257.
126. Balda MS, Gonzalez-Mariscal L, Contreras RG, et al. Assembly and sealing of tight junctions: possible participation of G-proteins, phospholipase C, protein kinase C and calmodulin. J Membr Biol. 1991;122:193-202.
127. Meyer TN, Schwesinger C, Denker BM. Zonula occludens-1 is a scaffolding protein for signaling molecules. Galpha (12) directly binds to the Src homology 3 domain and regulates paracellular permeability in epithelial cells. J Biol Chem. 2002;277:24855-24858.
128. Sabath E, Negoro H, Beaudry S, et al. Galpha12 regulates protein interactions within the MDCK cell tight junction and inhibits tight-junction assembly. J Cell Sci. 2008;121:814-824.
129. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43:246-252.
130. Herroeder S, Reichardt P, Sassmann A, et al. Guanine nucleotide-binding proteins of the G12 family shape immune functions by controlling CD4+ T cell adhesiveness and motility. Immunity. 2009;30:708-720.
131. Cottone M, Marrone C, Casa A, et al. Familial occurrence of inflammatory bowel disease in celiac disease. Inflamm Bowel Dis. 2003;9:321-323.
132. Schedel J, Rockmann F, Bongartz T, et al. Association of Crohn's disease and latent celiac disease: a case report and review of the literature. Int J Colorectal Dis. 2005;20:376-380.
133. Tursi A, Giorgetti GM, Brandimarte G, et al. High prevalence of celiac disease among patients affected by Crohn's disease. Inflamm Bowel Dis. 2005;11:662-666.
134. McGovern DP, Taylor KD, Landers C, et al. MAGI2 genetic variation and inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:75-83.
135. Ingham RJ, Colwill K, Howard C, et al. WW domains provide a platform for the assembly of multiprotein networks. Mol Cell Biol. 2005;25:7092-7106.
136. Wu X, Hepner K, Castelino-Prabhu S, et al. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci U S A. 2000;97:4233-4238.
137. Hu Y, Li Z, Guo L, et al. MAGI-2 Inhibits cell migration and proliferation via PTEN in human hepatocarcinoma cells. Arch Biochem Biophys. 2007;467:1-9.
138. Valiente M, Andres-Pons A, Gomar B, et al. Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-associated serine/threonine kinases. J Biol Chem. 2005;280:28936-28943.
139. Zeissig S, Bojarski C, Buergel N, et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut. 2004;53:1295-1302.
140. Inoue A, Saito J, Ikebe R, et al. Myosin IXb is a single-headed minusenddirected processive motor. Nat Cell Biol. 2002;4:302-306.
141. Post PL, Tyska MJ, O'Connell CB, et al. Myosin-IXb is a single-headed and processive motor. J Biol Chem. 2002;277:11679-11683.
142. Muller RT, Honnert U, Reinhard J, et al. The rat myosin myr 5 is a GTPase-activating protein for Rho in vivo: essential role of arginine 1695. Mol Biol Cell. 1997;8:2039-2053.
143. Bruewer M, Hopkins AM, Hobert ME, et al. RhoA, Rac1, and Cdc42 exert distinct effects on epithelial barrier via selective structural and biochemical modulation of junctional proteins and F-actin. Am J Physiol Cell Physiol. 2004;287:C327-C335.
144. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279:509-514.
145. Hopkins AM, Walsh SV, Verkade P, et al. Constitutive activation of Rho proteins by CNF-1 influences tight junction structure and epithelial barrier function. J Cell Sci. 2003;116:725-742.
146. Monsuur AJ, De Bakker PI, Alizadeh BZ, et al. Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat Genet. 2005;37:1341-1344.
147. Amundsen SS, Monsuur AJ, Wapenaar MC, et al. Association analysis of MYO9B gene polymorphisms with celiac disease in a Swedish/Norwegian cohort. Hum Immun. 2006;67:341-345.
148. Hunt KA, Monsuur AJ, McArdle WL, et al. Lack of association of MYO9B genetic variants with coeliac disease in a British cohort. Gut. 2006;55:969-972.
149. Van Bodegraven AA, Curley CR, Hunt KA, et al. Genetic variation in myosin IXB is associated with ulcerative colitis. Gastroenterology. 2006;131:1768-1774.
150. Cooney R, Cummings JR, Pathan S, et al. Association between genetic variants in myosin IXB and Crohn's disease. Inflamm Bowel Dis. 2009;15:1014-1021.
151. Nunez C, Oliver J, Mendoza JL, et al. MYO9B polymorphisms in patients with inflammatory bowel disease. Gut. 2007;56:1321-1322.
152. Wellcome Trust Case Control C. Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls. Nature. 2007;447:661-678.
153. Fasano A, Not T, Wang W, et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet. 2000;355:1518-1519.
154. Wang W, Uzzau S, Goldblum SE, et al. Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci. 2000;113:4435-4440.
155. Latiano A, Palmieri O, Valvano MR, et al. The association of MYO9B gene in Italian patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2008;27:241-248.
156. Sapone A, De Magistris L, Pietzak M, et al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes. 2006;55:1443-1449.
157. Chandhoke SK, Mooseker MS. A role for myosin IXb, a motor-RhoGAP chimera, in epithelial wound healing and tight junction regulation. Mol Biol Cell. 2012;23:2468-2480.
158. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet. 2007;39:830-832.
159. Waterman M, Xu W, Stempak JM, et al. Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis. Inflamm Bowel Dis. 2011;17:1936-1942.
160. Weersma RK, Stokkers PC, Cleynen I, et al. Confirmation of multiple Crohn's disease susceptibility loci in a large Dutch-Belgian cohort. Am J Gastroenterol. 2009;104:630-638.
161. Franke A, Balschun T, Karlsen TH, et al. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet. 2008;40:713-715.
162. Glas J, Wagner J, Seiderer J, et al. PTPN2 gene variants are associated with susceptibility to both Crohn's disease and ulcerative colitis supporting a common genetic disease background. PLoS One. 2012;7:e33682.
163. Scharl M, Wojtal KA, Becker HM, et al. Protein tyrosine phosphatase nonreceptor type 2 regulates autophagosome formation in human intestinal cells. Inflamm Bowel Dis. 2012;18:1287-1302.
164. Scharl M, Mwinyi J, Fischbeck A, et al. Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptideinduced cytokine secretion and autophagy. Inflamm Bowel Dis. 2012;18:900-912.
165. Yu W, Hegarty JP, Berg A, et al. PTPN2 is associated with Crohn's disease and its expression is regulated by NKX2-3. Dis Markers. 2012;32:83-91.
166. Pabst O, Zweigerdt R, Arnold HH. Targeted disruption of the homeobox transcription factor Nkx2-3 in mice results in postnatal lethality and abnormal development of small intestine and spleen. Development. 1999;126:2215-2225.
167. Cool DE, Tonks NK, Charbonneau H, et al. cDNA isolated from a human T-cell library encodes a member of the protein-tyrosine-phosphatase family. Proc Natl Acad Sci U S A. 1989;86:5257-5261.
168. Tiganis T, Bennett AM. Protein tyrosine phosphatase function: the substrate perspective. Biochem J. 2007;402:1-15.
169. Marcil V, Mack DR, Kumar V, et al. Association between the PTPN2 gene and Crohn's disease: dissection of potential causal variants. Inflamm Bowel Dis. 2013;19:1149-1155.
170. Scharl M, McCole DF, Weber A, et al. Protein tyrosine phosphatase N2 regulates TNFalpha-induced signalling and cytokine secretion in human intestinal epithelial cells. Gut. 2011;60:189-197.
171. Scharl M, Paul G, Weber A, et al. Protection of epithelial barrier function by the Crohn's disease associated gene protein tyrosine phosphatase n2. Gastroenterology. 2009;137:2030-2040. e2035.
172. Todd JA, Walker NM, Cooper JD, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet. 2007;39:857-864.
173. Amre DK, Mack DR, Morgan K, et al. Susceptibility loci reported in genome-wide association studies are associated with Crohn's disease in Canadian children. Aliment Pharmacol Ther. 2010;31:1186-1191.
174. Smyth DJ, Plagnol V, Walker NM, et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med. 2008;359:2767-2777.
175. Ibarra-Sanchez MJ, Simoncic PD, Nestel FR, et al. The T-cell protein tyrosine phosphatase. Semin Immunol. 2000;12:379-386.
176. Lorenzen JA, Dadabay CY, Fischer EH. COOH-terminal sequence motifs target the T cell protein tyrosine phosphatase to the ER and nucleus. J Cell Biol. 1995;131:631-643.
177. Tiganis T. PTP1B and TCPTP-nonredundant phosphatases in insulin signaling and glucose homeostasis. FEBS J. 2013;280:445-458.
178. Galic S, Hauser C, Kahn BB, et al. Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Mol Cell Biol. 2005;25:819-829.
179. Mattila E, Pellinen T, Nevo J, et al. Negative regulation of EGFR signalling through integrin-alpha1beta1-mediated activation of protein tyrosine phosphatase TCPTP. Nat Cell Biol. 2005;7:78-85.
180. Simoncic PD, Lee-Loy A, Barber DL, et al. The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. Curr Biol. 2002;12:446-453.
181. Ten Hoeve J, De Jesus Ibarra-Sanchez M, Fu Y, et al. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol. 2002;22:5662-5668.
182. Tiganis T, Bennett AM, Ravichandran KS, et al. Epidermal growth factor receptor and the adaptor protein p52Shc are specific substrates of T-cell protein tyrosine phosphatase. Mol Cell Biol. 1998;18:1622-1634.
183. Van Vliet C, Bukczynska PE, Puryer MA, et al. Selective regulation of tumor necrosis factor-induced Erk signaling by Src family kinases and the T cell protein tyrosine phosphatase. Nat Immunol. 2005;6:253-260.
184. Heinonen KM, Nestel FP, Newell EW, et al. T-cell protein tyrosine phosphatase deletion results in progressive systemic inflammatory disease. Blood. 2004;103:3457-3464.
185. You-Ten KE, Muise ES, Itie A, et al. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatasedeficient mice. J Exp Med. 1997;186:683-693.
186. Wiede F, Chew SH, Van Vliet C, et al. Strain-dependent differences in bone development, myeloid hyperplasia, morbidity and mortality in ptpn2-deficient mice. PLoS One. 2012;7:e36703.
187. Hassan SW, Doody KM, Hardy S, et al. Increased susceptibility to dextran sulfate sodium induced colitis in the T cell protein tyrosine phosphatase heterozygous mouse. PLoS One. 2010;5:e8868.
188. Uribe JM, McCole DF, Barrett KE. Interferon-gamma activates EGF receptor and increases TGF-alpha in T84 cells: implications for chloride secretion. American J Physiol Gastrointest Liver Physiol. 2002;283:G923-931.
189. Scharl M, Rudenko I, McCole DF. Loss of protein tyrosine phosphatase N2 potentiates epidermal growth factor suppression of intestinal epithelial chloride secretion. Am J Physiol Gastrointest Liver Physiol. 2010;299:G935-G945.
190. McCole DF. Regulation of epithelial barrier function by the inflammatory bowel disease candidate gene, PTPN2. Ann N Y Acad Sci. 2012;1257:108-114.
191. Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2009;41:56-65.
192. Marcil V, Sinnett D, Seidman E, et al. Association between genetic variants in the HNF4A gene and childhood-onset Crohn's disease. Genes Immun. 2012;13:556-565.
193. Yamagata K, Furuta H, Oda N, et al. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature. 1996;384:458-460.
194. Sladek FM, Zhong WM, Lai E, et al. Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev. 1990;4:2353-2365.
195. Garrison WD, Battle MA, Yang C, et al. Hepatocyte nuclear factor 4alpha is essential for embryonic development of the mouse colon. Gastroenterology. 2006;130:1207-1220.
196. Chen WS, Manova K, Weinstein DC, et al. Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm and impaired gastrulation of mouse embryos. Genes Dev. 1994;8:2466-2477.
197. Parviz F, Matullo C, Garrison WD, et al. Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. Nat Genet. 2003;34:292-296.
198. Ahn SH, Shah YM, Inoue J, et al. Hepatocyte nuclear factor 4 alpha in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:908-920.
199. Cattin AL, Le Beyec J, Barreau F, et al. Hepatocyte nuclear factor 4alpha, a key factor for homeostasis, cell architecture, and barrier function of the adult intestinal epithelium. Mol Cell Biol. 2009;29:6294-6308.
200. Darsigny M, Babeu JP, Dupuis AA, et al. Loss of hepatocyte-nuclearfactor-4alpha affects colonic ion transport and causes chronic inflammation resembling inflammatory bowel disease in mice. PLoS One. 2009;4:e7609.
201. Babeu JP, Darsigny M, Lussier CR, et al. Hepatocyte nuclear factor 4alpha contributes to an intestinal epithelial phenotype in vitro and plays a partial role in mouse intestinal epithelium differentiation. Am J Physiol Gastrointest Liver Physiol. 2009;297:G124-G134.
202. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22:337-358.
203. Chellappa K, Jankova L, Schnabl JM, et al. Src tyrosine kinase phosphorylation of nuclear receptor HNF4alpha correlates with isoformspecific loss of HNF4alpha in human colon cancer. Proc Natl Acad Sci U S A. 2012;109:2302-2307.
204. Anderson CA, Massey DC, Barrett JC, et al. Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology. 2009;136:523-529. e523.
205. Fisher SA, Tremelling M, Anderson CA, et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet. 2008;40:710-712.
206. Festen EA, Stokkers PC, Van Diemen CC, et al. Genetic analysis in a Dutch study sample identifies more ulcerative colitis susceptibility loci and shows their additive role in disease risk. Am J Gastroenterol. 2010;105:395-402.
207. Sercu S, Zhang M, Oyama N, et al. Interaction of extracellular matrix protein 1 with extracellular matrix components: ECM1 is a basement membrane protein of the skin. J Invest Dermatol. 2008;128:1397-1408.
208. Chan I, South AP, McGrath JA, et al. Rapid diagnosis of lipoid proteinosis using an anti-extracellular matrix protein 1 (ECM1) antibody. J Dermatol Sci. 2004;35:151-153.
209. Li AC, Thompson RP. Basement membrane components. J Clin Pathol. 2003;56:885-887.
210. Kenny PA, Enver T, Ashworth A. Receptor and secreted targets of Wnt-1/beta-catenin signalling in mouse mammary epithelial cells. BMC Cancer. 2005;5:3.
211. Fujimoto N, Terlizzi J, Aho S, et al. Extracellular matrix protein 1 inhibits the activity of matrix metalloproteinase 9 through high-affinity protein/protein interactions. Exp Dermatol. 2006;15:300-307.
212. Garg P, Vijay-Kumar M, Wang L, et al. Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. Am J Physiol Gastrointest Liver Physiol. 2009;296:G175-G184.
213. Wang L, Yu J, Ni J, et al. Extracellular matrix protein 1 (ECM1) is overexpressed in malignant epithelial tumors. Cancer Lett. 2003;200:57-67.
214. Satsangi J, Parkes M, Louis E, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet. 1996;14:199-202.
215. Buisine MP, Desreumaux P, Debailleul V, et al. Abnormalities in mucin gene expression in Crohn's disease. Inflamm Bowel Dis. 1999;5:24-32.
216. Tysk C, Riedesel H, Lindberg E, et al. Colonic glycoproteins in monozygotic twins with inflammatory bowel disease. Gastroenterology. 1991;100:419-423.
217. Kyo K, Parkes M, Takei Y, et al. Association of ulcerative colitis with rare VNTR alleles of the human intestinal mucin gene, MUC3. Hum Mol Genet. 1999;8:307-311.
218. Kyo K, Muto T, Nagawa H, et al. Associations of distinct variants of the intestinal mucin gene MUC3A with ulcerative colitis and Crohn's disease. J Hum Genet. 2001;46:5-20.
219. Van Den Steen P, Rudd PM, Dwek RA, et al. Concepts and principles of O-linked glycosylation. Crit Rev Biochem Mol Biol. 1998;33:151-208.
220. Variyam EP, Hoskins LC. Mucin degradation in human colon ecosystems. Degradation of hog gastric mucin by fecal extracts and fecal cultures. Gastroenterology. 1981;81:751-758.
221. Raouf AH, Tsai HH, Parker N, et al. Sulphation of colonic and rectal mucin in inflammatory bowel disease: reduced sulphation of rectal mucus in ulcerative colitis. Clin Sci (Lond). 1992;83:623-626.
222. Williams SJ, Munster DJ, Quin RJ, et al. The MUC3 gene encodes a transmembrane mucin and is alternatively spliced. Biochem Biophys Res Commun. 1999;261:83-89.
223. Pelaseyed T, Hansson GC. CFTR anion channel modulates expression of human transmembrane mucin MUC3 through the PDZ protein GOPC. J Cell Sci. 2011;124:3074-3083.
224. Danoy P, Pryce K, Hadler J, et al. Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet. 2010;6:e1001195.
225. Kumar V, Mack DR, Marcil V, et al. Genome-wide association study signal at the 12q12 locus for Crohn's disease may represent associations with the MUC19 gene. Inflamm Bowel Dis. 2013;19:1254-1259.
226. Rivas MA, Beaudoin M, Gardet A, et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet. 2011;43:1066-1073.
227. Fallon MA, Latchney LR, Hand AR, et al. The sld mutation is specific for sublingual salivary mucous cells and disrupts apomucin gene expression. Physiol Genomics. 2003;14:95-106.
228. Das B, Cash MN, Hand AR, et al. Tissue distibution of murine Muc19/smgc gene products. J Histochem Cytochem. 2010;58:141-156.
229. Plauth M, Jenss H, Meyle J. Oral manifestations of Crohn's disease. An analysis of 79 cases. J Clin Gastroenterol. 1991;13:29-37.
230. Wrackmeyer U, Hansen GH, Seya T, et al. Intelectin: a novel lipid raftassociated protein in the enterocyte brush border. Biochemistry. 2006;45:9188-9197.
231. Tsuji S, Uehori J, Matsumoto M, et al. Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem. 2001;276:23456-23463.
232. Tsuji S, Yamashita M, Nishiyama A, et al. Differential structure and activity between human and mouse intelectin-1: human intelectin-1 is a disulfide-linked trimer, whereas mouse homologue is a monomer. Glycobiology. 2007;17:1045-1051.
233. Komiya T, Tanigawa Y, Hirohashi S. Cloning of the novel gene intelectin, which is expressed in intestinal paneth cells in mice. Biochem Biophys Res Commun. 1998;251:759-762.
234. Pemberton AD, Knight PA, Gamble J, et al. Innate BALB/c enteric epithelial responses to Trichinella spiralis: inducible expression of a novel goblet cell lectin, intelectin-2, and its natural deletion in C57BL/10 mice. J Immunol. 2004;173:1894-1901.
235. Akiyama Y, Oshima K, Kuhara T, et al. A lactoferrin-receptor, intelectin 1, affects uptake, sub-cellular localization and release of immunochemically detectable lactoferrin by intestinal epithelial Caco-2 cells. J Biochem. 2013;154:437-448.
236. Suzuki YA, Shin K, Lonnerdal B. Molecular cloning and functional expression of a human intestinal lactoferrin receptor. Biochemistry. 2001;40:15771-15779.
237. Schaffler A, Neumeier M, Herfarth H, et al. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta. 2005;1732:96-102.
238. De Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007;56:1655-1661.
239. Yamawaki H, Kuramoto J, Kameshima S, et al. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun. 2011;408:339-343.
240. Zhou Z, Liu H, Gu G, et al. Immunoproteomic to identify antigens in the intestinal mucosa of Crohn's disease patients. PLoS One. 2013;8:e81662.
241. Lu Y, Zhou L, Liu L, et al. Serum omentin-1 as a disease activity marker for Crohn's disease. Dis Markers. 2014:194-202.
242. Duraes C, Machado JC, Portela F, et al. Phenotype-genotype profiles in Crohn's disease predicted by genetic markers in autophagy-related genes (GOIA study II). Inflamm Bowel Dis. 2013;19:230-239.
243. Schaffler A, Zeitoun M, Wobser H, et al. Frequency and significance of the novel single nucleotide missense polymorphism Val109Asp in the human gene encoding omentin in Caucasian patients with type 2 diabetes mellitus or chronic inflammatory bowel diseases. Cardiovasc Diabetol. 2007;6:3.
244. Pemberton AD, Rose-Zerilli MJ, Holloway JW, et al. A singlenucleotide polymorphism in intelectin 1 is associated with increased asthma risk. J Allergy Clin Immunol. 2008;122:1033-1034.
245. Doursout MF, Horton H, Hoang L, et al. Lactoferrin moderates LPSinduced hypotensive response and gut injury in rats. Int Immunopharmacol. 2013;15:227-231.
246. Flores-Villasenor H, Canizalez-Roman A, Velazquez-Roman J, et al. Protective effects of lactoferrin chimera and bovine lactoferrin in a mouse model of enterohaemorrhagic Escherichia coli O157:H7 infection. Biochem Cell Biol. 2012;90:405-411.
247. Carlberg C, Campbell MJ. Vitamin D receptor signaling mechanisms: integrated actions of a well-defined transcription factor. Steroids. 2013;78:127-136.
248. Simmons JD, Mullighan C, Welsh KI, et al. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut. 2000;47:211-214.
249. Renkema KY, Alexander RT, Bindels RJ, et al. Calcium and phosphate homeostasis: concerted interplay of new regulators. Ann Med. 2008;40:82-91.
250. Koeffler HP. Vitamin D: myeloid differentiation and proliferation. Haematol Blood Transfus. 1985;29:409-417.
251. D'Ambrosio D, Cippitelli M, Cocciolo MG, et al. Inhibition of IL-12 production by 1, 25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest. 1998;101:252-262.
252. Lemire JM, Archer DC, Beck L, et al. Immunosuppressive actions of 1, 25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr. 1995;125:1704S-1708S.
253. Rook GA, Steele J, Fraher L, et al. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology. 1986;57:159-163.
254. Duerr RH, Barmada MM, Zhang L, et al. Linkage and association between inflammatory bowel disease and a locus on chromosome 12. Am J Hum Genet. 1998;63:95-100.
255. Morrison NA, Qi JC, Tokita A, et al. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367:284-287.
256. Verbeek W, Gombart AF, Shiohara M, et al. Vitamin D receptor: no evidence for allele-specific mRNA stability in cells which are heterozygous for the Taq I restriction enzyme polymorphism. Biochem Biophys Res Commun. 1997;238:77-80.
257. Dresner-Pollak R, Ackerman Z, Eliakim R, et al. The BsmI vitamin D receptor gene polymorphism is associated with ulcerative colitis in Jewish Ashkenazi patients. Genet Test. 2004;8:417-420.
258. Xue LN, Xu KQ, Zhang W, et al. Associations between vitamin D receptor polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a meta-analysis. Inflamm Bowel Dis. 2013;19:54-60.
259. Naderi N, Farnood A, Habibi M, et al. NOD2 exonic variations in Iranian Crohn's disease patients. Int J Colorect Dis. 2011;26:775-781.
260. Hughes DJ, McManus R, Neary P, et al. Common variation in the vitamin D receptor gene and risk of inflammatory bowel disease in an Irish case-control study. Eur J Gastroenterol Hepatol. 2011;23:807-812.
261. Noble CL, McCullough J, Ho W, et al. Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:588-596.
262. Froicu M, Weaver V, Wynn TA, et al. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol. 2003;17:2386-2392.
263. Kong J, Zhang Z, Musch MW, et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol. 2008;294:G208-G216.
264. Kim JH, Yamaori S, Tanabe T, et al. Implication of intestinal VDR deficiency in inflammatory bowel disease. Biochim Biophys Acta. 2013;1830:2118-2128.
265. Schepens MA, Schonewille AJ, Vink C, et al. Supplemental calcium attenuates the colitis-related increase in diarrhea, intestinal permeability, and extracellular matrix breakdown in HLA-B27 transgenic rats. J Nutr. 2009;139:1525-1533.
266. Laverny G, Penna G, Vetrano S, et al. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Immunol Lett. 2010;131:49-58.
267. Libioulle C, Louis E, Hansoul S, et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet. 2007;3:e58.
268. Franke A, Hampe J, Rosenstiel P, et al. Systematic association mapping identifies NELL1 as a novel IBD disease gene. PLoS One. 2007;2:e691.
269. Glas J, Seiderer J, Czamara D, et al. PTGER4 expression-modulating polymorphisms in the 5p13.1 region predispose to Crohn's disease and affect NF-kappaB and XBP1 binding sites. PLoS One. 2012;7:e52873.
270. Nitta M, Hirata I, Toshina K, et al. Expression of the EP4 prostaglandin E2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1-329. Scand J Immunol. 2002;56:66-75.
271. Wallace JL. Prostaglandin biology in inflammatory bowel disease. Gastroenterol Clin North Am. 2001;30:971-980.
272. Jiang GL, Nieves A, Im WB, et al. The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. J Pharmacol Exp Ther. 2007;320:22-28.
273. Kabashima K, Saji T, Murata T, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002;109:883-893.
274. Chen Q, Muramoto K, Masaaki N, et al. A novel antagonist of the prostaglandin E (2) EP (4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol. 2010;160:292-310.
275. Clark P, Rowland SE, Denis D, et al. MF498 [N-{[4-(5, 9-Diethoxy-6-oxo-6, 8-dihydro-7H-pyrrolo[3, 4-g]quinolin-7-yl)-3-methylbe nzyl]sulfonyl}-2-(2-methoxyphenyl) acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. J Pharmacol Exp Ther. 2008;325:425-434.
276. Yao C, Sakata D, Esaki Y, et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med. 2009;15:633-640.
277. Yu Y, Chadee K. Prostaglandin E2 stimulates IL-8 gene expression in human colonic epithelial cells by a posttranscriptional mechanism. J Immunol. 1998;161:3746-3752.
278. Rodriguez-Lagunas MJ, Martin-Venegas R, Moreno JJ, et al. PGE2 promotes Ca2+-mediated epithelial barrier disruption through EP1 and EP4 receptors in Caco-2 cell monolayers. Am J Physiol Cell Physiol. 2010;299:C324-C334.
279. Lejeune M, Leung P, Beck PL, et al. Role of EP4 receptor and prostaglandin transporter in prostaglandin E2-induced alteration in colonic epithelial barrier integrity. Am J Physiol Gastrointest Liver Physiol. 2010;299:G1097-G1105.
280. Gookin JL, Galanko JA, Blikslager AT, et al. PG-mediated closure of paracellular pathway and not restitution is the primary determinant of barrier recovery in acutely injured porcine ileum. Am J Physiol Gastrointest Liver Physiol. 2003;285:G967-G979.
281. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucinerich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603.
282. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
283. Henckaerts L, Vermeire S. NOD2/CARD15 disease associations other than Crohn's disease. Inflamm Bowel Dis. 2007;13:235-241.
284. Buhner S, Buning C, Genschel J, et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut. 2006;55:342-347.
285. Kosovac K, Brenmoehl J, Holler E, et al. Association of the NOD2 genotype with bacterial translocation via altered cell-cell contacts in Crohn's disease patients. Inflamm Bowel Dis. 2010;16:1311-1321.
286. Ferby I, Reschke M, Kudlacek O, et al. Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med. 2006;12:568-573.
287. Fiorentino L, Pertica C, Fiorini M, et al. Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol Cell Biol. 2000;20:7735-7750.
288. Hackel PO, Gishizky M, Ullrich A. Mig-6 is a negative regulator of the epidermal growth factor receptor signal. Biol Chem. 2001;382:1649-1662.
289. Hopkins S, Linderoth E, Hantschel O, et al. Mig6 is a sensor of EGF receptor inactivation that directly activates c-Abl to induce apoptosis during epithelial homeostasis. Dev Cell. 2012;23:547-559.
290. Banan A, Fields JZ, Zhang Y, et al. Key role of PKC and Ca2+ in EGF protection of microtubules and intestinal barrier against oxidants. Am J Physiol Gastrointest Liver Physiol. 2001;280:G828-G843.
291. Frey MR, Golovin A, Polk DB. Epidermal growth factor-stimulated intestinal epithelial cell migration requires Src family kinase-dependent p38 MAPK signaling. J Biol Chem. 2004;279:44513-44521.
292. McCole DF, Rogler G, Varki N, et al. Epidermal growth factor partially restores colonic ion transport responses in mouse models of chronic colitis. Gastroenterology. 2005;129:591-608.
293. Wright NA, Pike C, Elia G. Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in human gastrointestinal stem cells. Nature. 1990;343:82-85.
294. Yamaoka T, Frey MR, Dise RS, et al. Specific epidermal growth factor receptor autophosphorylation sites promote mouse colon epithelial cell chemotaxis and restitution. Am J Physiol Gastrointest Liver Physiol. 2011;301:G368-G376.
295. Forsyth CB, Banan A, Farhadi A, et al. Regulation of oxidant-induced intestinal permeability by metalloprotease-dependent epidermal growth factor receptor signaling. J Pharmacol Exp Ther. 2007;321:84-97.
296. Raimondi F, Santoro P, Barone MV, et al. Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. Am J Physiol Gastrointest Liver Physiol. 2008;294:G906-G913.
297. Tripathi A, Lammers KM, Goldblum S, et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci U S A. 2009;106:16799-16804.
298. Plevy S, Silverberg MS, Lockton S, et al. Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patients. Inflamm Bowel Dis. 2013;19:1139-1148.
299. Toedter G, Li K, Sague S, et al. Genes associated with intestinal permeability in ulcerative colitis: changes in expression following infliximab therapy. Inflamm Bowel Dis. 2012;18:1399-1410.